Patent US5756476A successfully refreshed from Google Patents.
US5756476A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Inhibition of cell proliferation using antisense oligonucleotides
Assignee: United States Department of Health and Human Services
•
Filing: 1994-01-26
•
Granted: 1998-05-26
•
Expires: 2014-01-26
Abstract
Abstract The present invention provides a method of inhibiting restenosis of a blood vessel in a mammal after mechanical treatment of the vessel to reduce a stenosis. The method includes contacting proliferating smooth muscle cells in the vessel with an antisense oligonucleotide directed against a cellular division cycle gene product. This gene product can be one of the following: c-myc, PCNA, and cyclin B 1 . The antisense oligonucleotide is used in an amount effective to inhibit translation of the cellular division cycle gene product in the cell.
Inventors
- 👤 Stephen E. Epstein
- 👤 Edith H. Speir
- 👤 Ellis F. Unger
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 20:14
CPC Classifications
C; C12; C12N; C12N15/00; C12N15/09; C12N15/11; C12N15/113; C12N15/1135; A; A61; A61K; A61K38/00; C12N2310/00; C12N2310/30; C12N2310/31; C12N2310/314; C12N2799/00; C12N2799/02; C12N2799/021
Claims Analysis
Total Claims: 22
Claim 1
Independent Claim
42 words
A method of inhibiting the growth of a human smooth muscle cell, comprising contacting said cell with a synthetic antisense oligonucleotide directed against a c-myc gene product in an amount effective to inhibit translation of said c-myc gene product in said cell.
Claim 2
Independent Claim
42 words
A method of inhibiting the growth of a human smooth muscle cell, comprising contacting said cell with a synthetic antisense oligonucleotide directed against a c-myc gene product in an amount effective to inhibit translation of said c-myc gene product in said cell.
Claim 3
Dependent Claim
57 words
The method of claim 1 wherein said c-myc gene product has an AUG translation initiation codon, and said synthetic antisense oligonucleotide is complementary to a portion of a 27 nucleotide sequence of said c-myc gene product extending from two codons upstream of the AUG translation initiation codon to six codons downstream of the AUG translation initiation codon.
Claim 4
Dependent Claim
38 words
The method of claim 2 wherein said synthetic antisense oligonucleotide is complementary to a region of said c-myc gene product that extends from said AUG translation initiation codon to four codons downstream of said AUG translation initiation codon.
Claim 5
Dependent Claim
20 words
The method of claim 3 wherein said synthetic antisense oligonucleotide is chemically modified with phosphoramidate linkages to block exonucleolytic degradation.
Claim 6
Dependent Claim
42 words
The method of claim 2 wherein said synthetic antisense oligonucleotide is complementary to a region of said c-myc gene product that extends from one codon upstream of said AUG translation initiation codon to four codons downstream of said AUG translation initiation codon.
Claim 7
Dependent Claim
20 words
The method of claim 5 wherein said synthetic antisense oligonucleotide is chemically modified with phosphoramidate linkages to block exonucleolytic degradation.
Claim 8
Independent Claim
42 words
A method of inhibiting the migration of a human smooth muscle cell, comprising contacting said cell with a synthetic antisense oligonucleotide directed against a c-myc gene product in an amount effective to inhibit translation of said c-myc gene product in said cell.
Claim 9
Independent Claim
42 words
A method of inhibiting the migration of a human smooth muscle cell, comprising contacting said cell with a synthetic antisense oligonucleotide directed against a c-myc gene product in an amount effective to inhibit translation of said c-myc gene product in said cell.
Claim 10
Dependent Claim
57 words
The method of claim 7 wherein said c-myc gene product has an AUG translation initiation codon, and said synthetic antisense oligonucleotide is complementary to a portion of a 27 nucleotide sequence of said c-myc gene product extending from two codons upstream of the AUG translation initiation codon to six codons downstream of the AUG translation initiation codon.
Claim 11
Dependent Claim
38 words
The method of claim 8 wherein said synthetic antisense oligonucleotide is complementary to a region of said c-myc gene product that extends from said AUG translation initiation codon to four codons downstream of said AUG translation initiation codon.
Claim 12
Dependent Claim
20 words
The method of claim 9 wherein said synthetic antisense oligonucleotide is chemically modified with phosphoramidate linkages to block exonucleolytic degradation.
Claim 13
Dependent Claim
42 words
The method of claim 9 wherein said synthetic antisense oligonucleotide is complementary to a region of said c-myc gene product that extends from one codon upstream of said AUG translation initiation codon to four codons downstream of said AUG translation initiation codon.
Claim 14
Dependent Claim
20 words
The method of claim 11 herein said synthetic antisense oligonucleotide is chemically modified with phosphoramidate linkages to block exonucleolytic degradation.
Claim 15
Independent Claim
57 words
A method of inhibiting restenosis of a blood vessel in a human after mechanical treatment of the vessel to reduce a stenosis, the method comprising contacting the vessel with a synthetic antisense oligonucleotide directed against a c-myc gene product in an amount effective to inhibit translation of said c-myc gene product in the cells of the vessel.
Claim 16
Independent Claim
57 words
A method of inhibiting restenosis of a blood vessel in a human after mechanical treatment of the vessel to reduce a stenosis, the method comprising contacting the vessel with a synthetic antisense oligonucleotide directed against a c-myc gene product in an amount effective to inhibit translation of said c-myc gene product in the cells of the vessel.
Claim 17
Dependent Claim
57 words
The method of claim 13 wherein said c-myc gene product has an AUG translation initiation codon, and said synthetic antisense oligonucleotide is complementary to a portion of a 27 nucleotide sequence of said c-myc gene product extending from two codons upstream of the AUG translation initiation codon to six codons downstream of the AUG translation initiation codon.
Claim 18
Dependent Claim
38 words
The method of claim 14 wherein said synthetic antisense oligonucleotide is complementary to a region of said c-myc gene product that extends from said AUG translation initiation codon to four codons downstream of said AUG translation initiation codon.
Claim 19
Dependent Claim
20 words
The method of claim 15 wherein said synthetic antisense oligonucleotide is chemically modified with phosphoramidate linkages to block exonucleolytic degradation.
Claim 20
Dependent Claim
12 words
The method of claim 16 wherein said mechanical treatment is cardiac angioplasty.
Claim 21
Dependent Claim
42 words
The method of claim 16 wherein said synthetic antisense oligonucleotide is complementary to a region of said c-myc gene product that extends from one codon upstream of said AUG translation initiation codon to four codons downstream of said AUG translation initiation codon.
Claim 22
Dependent Claim
20 words
The method of claim 18 wherein said synthetic antisense oligonucleotide is chemically modified with phosphorapidate linkages to block exonucleolytic degradation.
References Cited (Backward Citations)
US5023243A
Cited
US5593974A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2001-05-25 | 2001-11-24 | 2002-05-26 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2005-05-25 | 2005-11-24 | 2006-05-26 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2009-05-25 | 2009-11-24 | 2010-05-26 | $7700.00 | Window Closed / Lapsed |